Table 21.

Advantages and Disadvantages of DPP-4 Inhibitors

AdvantagesDisadvantages
No hypoglycemiaPancreatic disease
Weight neutralHeart failure (saxagliptin/alogliptin)?
Decreases postprandial glucoseArthritis
Once a dayBullous pemphigoid
Well toleratedRelatively expensive
Decreases BPModest glycemic lowering

From: Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes

Cover of Endotext
Endotext [Internet].
Feingold KR, Anawalt B, Blackman MR, et al., editors.
South Dartmouth (MA): MDText.com, Inc.; 2000-.
Copyright © 2000-2024, MDText.com, Inc.

This electronic version has been made freely available under a Creative Commons (CC-BY-NC-ND) license. A copy of the license can be viewed at http://creativecommons.org/licenses/by-nc-nd/2.0/.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.